产品
编 号：F460570
分子式：C16H16ClNO4S
分子量：353.82
分子式：C16H16ClNO4S
分子量：353.82
产品类型
规格
价格
是否有货
结构图
CAS No: 79094-20-5
产品详情
生物活性：
Daltroban (BM-13505) is a selective and specific thromboxane A2 (TXA2) receptor antagonist. Daltroban increase intracellular calcium in vascular smooth muscle cells. Daltroban shows protective effect in reperfusion injury.
体内研究：
Daltroban (BM-13505) (1 mg/kg; i.v.; per hour) exerts protective effect in reperfusion injury following acute myocardial ischemia in cats.In comparison with vehicle (physiological saline)-treated cats, Daltroban (20 mg/kg per hour i.v.) reduces the ischaemia-induced rise in the ST segment and prevented the development of a Q-wave in the ECG during reperfusion. Daltroban protects the myocardium from ischaemic injury and that this effect involves prevention of ischaemia-induced leukocytosis.Animal Model:Adult male cats (2.8 to 4.6 kg; anesthetized cat model)
Dosage:1 mg/kg
Administration: i.v.; 30 minutes before reperfusion at a rate of 1 mg/kg followed by 1 mg/kg/hour
Result:Significantly reduced the area of ischemic tissue as a percent of total left ventricular mass and total area at risk, without altering basic hemodynamics and thereby not influencing myocardial oxygen demand.
Daltroban (BM-13505) is a selective and specific thromboxane A2 (TXA2) receptor antagonist. Daltroban increase intracellular calcium in vascular smooth muscle cells. Daltroban shows protective effect in reperfusion injury.
体内研究：
Daltroban (BM-13505) (1 mg/kg; i.v.; per hour) exerts protective effect in reperfusion injury following acute myocardial ischemia in cats.In comparison with vehicle (physiological saline)-treated cats, Daltroban (20 mg/kg per hour i.v.) reduces the ischaemia-induced rise in the ST segment and prevented the development of a Q-wave in the ECG during reperfusion. Daltroban protects the myocardium from ischaemic injury and that this effect involves prevention of ischaemia-induced leukocytosis.Animal Model:Adult male cats (2.8 to 4.6 kg; anesthetized cat model)
Dosage:1 mg/kg
Administration: i.v.; 30 minutes before reperfusion at a rate of 1 mg/kg followed by 1 mg/kg/hour
Result:Significantly reduced the area of ischemic tissue as a percent of total left ventricular mass and total area at risk, without altering basic hemodynamics and thereby not influencing myocardial oxygen demand.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备